跳到主要內容

研究成果

2020年論文發表

  1. Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N. Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatol Res. 2020 Oct;50(10):1109-1117
  2. Chang FY, Chen HC, Chen PJ, Ho MS, Hsieh SL, Lin JC, Liu FT, Sytwu HK. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). Version 2. J Biomed Sci. 2020 Jun 4;27(1):72.
  3. Chang KC, Tsai JH, Su TH. A Mysterious Case of Jaundice After Development of Skin Vesicles. Gastroenterology. 2020 Nov;159(5):1669-1671.
  4. Chang KT, Liu CJ, Tsai HT, Hsu TP, Chen PT, Hu SH. Effects and safety of body positioning on back pain after transcatheter arterial chemoembolization in people with hepatocellular carcinoma: A randomized controlled study. Int J Nurs Stud. 2020 Sep;109:103641
  5. Chang KV, Chen YC, Wu WT, Shen HJ, Huang KC, Chu HP, Han DS. Expression of telomeric repeat-containing RNA decreases in sarcopenia and increases after exercise and nutrition intervention. Nutrients. 2020 Dec 8;12(12):3766. (SCI)
  6. Chang KV, Wu WT, Huang KC, Han DS. Segmental body composition transitions in stroke patients: Trunks are different from extremities and strokes are as important as hemiparesis. Clin Nutr. 2020 Jun; 39(6): 1968-73. (SCI)
  7. Chang WY, Chiu YC, Chiu FW, Hsu YC, Tseng TC, Cheng PN, Yang SS, Liu CJ, Su TH, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. J Infect Dis. 2020 Sep 14;222(8):1345-1352
  8. Chao CT, Lee YH, Li CM, Han DS, Huang JW, Huang KC. Advanced age and chronic kidney disease modify the association between metabolic syndrome and frailty among community-dwelling elderly. Rejuvenation Res. 2020 Aug;23(4):333-340. (SCI)
  9. Chao CT, Yeh HY, Han DS, Huang JW, Huang KC. Determinants of circulating microRNA-125b, a risk predictor of vascular calcification, among community-dwelling older adults. Clin Transl Med. 2020 Aug;10(4):e145. (corresponding author) (SCI)
  10. Chaw SM, Tai JH, Chen SL, Hsieh CH, Chang SY, Yeh SH, Yang WS, Chen PJ, Wang HY. The origin and underlying driving forces of the SARS-CoV-2 outbreak. Version 2. J Biomed Sci. 2020 Jun 7;27(1):73.
  11. Chen JY, Wu JF, Kimura A, Nittono H, Liou BY, Lee CS, Chen HS, Chiu YC, Ni YH, Peng SS, Lee WT, Tsai IJ, Chang MH, Chen HL. AKR1D1 and CYP7B1 mutations in patients with inborn errors of bile acid metabolism: Possibly underdiagnosed diseases. Pediatr Neonatol. 2020 Feb;61(1):75-83.
  12. Chen PJ, Kao JH, Liu CJ, Yang HC. In Memoriam: Dr. Ding-Shinn Chen, 1943-2020. Hepatology. 2020 Nov;72(5):1890-1892.
  13. Chen TP, Lai M, Lin WY, Huang KC, Yang KC. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. J Gastroenterol Hepatol. 2020 Sep;35(9):1636-1643. (SCI)
  14. Cheng CL, Huang SC, Chen JH, Wei CH, Fang WQ, Su TH, Yuan CT, Liu JH, Chuang MK, Tien HF. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. Oncologist. 2020 Sep;25(9):793-802.
  15. Cheng PN, Chen CY, Yu ML, Lin CC, Lin CY, Peng CY, Tseng KC, Lo CC, Tseng IH, Liu CJ. Elbasvir / grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. J Microbiol Immunol Infect 2020
  16. Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ, Chen PJ, Gaggar A, Suri V, Mücke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K, Liang TJ. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest 2020 Mar 12. pii: 135616.
  17. Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH, Tao MH, Ho TC, Wu PY, Jang LT, Chen PJ, Chang SY, Yeh SH. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. Cell Rep. 2020 Oct 13;33(2):108254
  18. Chia JS, Chen HY, Ho CM, Jeng YM, Chen HL. Existence of follicular helper T cells in an isolated IgG4-related hepatic inflammatory pseudotumor. J Gastrointestin Liver Dis. 2020 Dec 12;29(4):499
  19. Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):533-542
  20. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020 Dec;14(6):889-919
  21. Ho CM, Chen YH, Chien CS, Ho SL, Chen HL, Hu RH, Lee PH. Hepatocyte and mesenchymal stem cell co-transplantation in rats of acute liver failure. J Korean Soc Transplant 2020 June; 34(2): 100-108
  22. Ho CM, Hu RH, Lee PH. Significance of offspring donors on long-term survival in adult living donor liver transplantation: Asian experience. Transplantation. 2020 Oct;104(10):e306
  23. Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: A nationwide cohort analysis. Frontiers in Oncology 2020 in press
  24. Ho TC, Wang EY, Yeh KH, Jeng YM, Horng JH, Wu LL, Chen YT, Huang HC, Hsu CL, Chen PJ, Yeh SH, Chen DS. Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6717-6725.
  25. Hong CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, Kao JH, Liu CJ. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. J Microbiol Immunol Infect. 2020 Aug;53(4):569-577.
  26. Hong TC, Yang HC, Chen CL, Kao JH, Liu CJ, Chen MJ, Wang HY, Kuo YC, Yu LY, Hu KC. Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. PLoS One. 2020 Oct 13;15(10):e0240445.
  27. Horng JH, Lin WH, Wu CR, Lin YY, Wu LL, Chen DS, Chen PJ. HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. J Biomed Sci. 2020 May 28;27(1):70.
  28. Hsiao CY, Hu RH, Ho CM, Wu YM, Lee PH, Ho MC. Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study. Am J Surg. 2020 Oct;220(4):958-964
  29. Hsiao CY, Teng X, Su TH, Lee PH, Kao JH, Huang KW. Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection. Clinics and Research in Hepatology and Gastroenterology. 2020.Feburary;44(1):12-20.
  30. Hsiao CY, Yang PC, Li X, Huang KW. Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma. Sci Rep. 2020 Jul 2;10(1):10883.
  31. Hsiao MY, Chang KV, Wu WT, Huang KC, Han DS. Grip strength and demographic variables estimate appendicular muscle mass better than bioelectrical impedance in Taiwanese older persons. J Am Med Dir Assoc. 2020 Sep 15:S1525-8610(20)30693-9. (SCI)
  32. Hsu CS, Liu WL, Li Q, Lowey B, Hertz L, Chao YC, Liang TJ, Chen DS, Kao JH. Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. J Formos Med Assoc. 2020 Sep;119(9):1382-139
  33. Hsu HY, Chen HL, Wu JF, Ni YH, Chang KC, Chiang CL, Lee CN, Zhao LL, Lai MW, Mu SC, Wen WH, Lin LH, Chang MH; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study). Occult hepatitis B virus infection in immunized infants born to untreated and tenofovir-treated highly viremic mothers. Clin Gastroenterol Hepatol. 2020 Jul 23:S1542-3565(20)31003-X
  34. Hsu SJ, Enkhzaya S, Lin YY, Tseng TC, Khosbayar T, Tsai CH, Wang TS, Enkhtuya D, Ivshinkhorol D, Naranzul N, Jargalsaikhan B, Amarsanaa J, Baatarkhuu O, Kao JH. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. J Formos Med Assoc. 2020 Mar;119(3):712-719.
  35. Hsu SJ, Yang SS, Kao JH. Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? J Formos Med Assoc. 2020 Jan;119(1 Pt 1):3-11.
  36. Hsu SJ, Yu ML, Su CW, Peng CY, Chien RN, Lin HH, Lo GH, Su WW, Kuo HT, Hsu CW, Yang SS, Yang SS, Tseng KC, Qin A, Huang YW, Chuang WL. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. J Formos Med Assoc. 2020 Oct 16:S0929-6646(20)30459-9
  37. Hsu WF, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Tsai PC, Huang JF, Dai CY, Chuang WL, Yu ML, Peng CY. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. Sci Rep 2020 Mar 25;10(1):5372.
  38. Hsu WY, Chang HH, Lu MY, Yang YL, Jou ST, Chen HL, Ni YH, Hsu HY, Chang MH, Wu JF. Clinical risk stratification of children with SIOPEL high-risk hepatoblastoma in Taiwan. Pediatr Neonatol. 2020 Aug;61(4):393-398
  39. Huang BY, Tsai MR, Hsu JK, Lin CY, Lin CL, Hu JT, Huang YW, Liu CJ, Wu WJ, Wu CF, Sung FY, Chen PJ, Liang HJ, Lin SM, Yu MW. Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. Mol Carcinog. 2020 Nov;59(11):1269-1279
  40. Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Yu ML. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol. 2020 Aug;115(8):1226-1235.
  41. Huang CY, Chang MH, Chen HL, Ni YH, Hsu HY, Wu JF. Bilirubin level 1 week after hepatoportoenterostomy predicts native liver survival in biliary atresia. Pediatr Res 2020; 87(4):730-734.
  42. Huang KW, Reebye V, Czysz K, Ciriello S, Dorman S, Reccia I, Lai HS, Peng L, Kostomitsopoulos N, Nicholls J, Habib RS, Tomalia DA, Sætrom P, Wilkes E, Cutillas P, Rossi JJ, Habib NA. Liver activation of Hepatocellular Nuclear Factor-4α by small activating RNA rescues dyslipidemia and improves metabolic profile. Molecular Therapy-Nucleic Acid. 2020 March 6(19):361-370.
  43. Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):565-578
  44. Huang YW, Hsu CW, Lu SN, Yu ML, Su CW, Su WW, Chien RN, Hsu CS, Hsu SJ, Lai HC, Qin A, Tseng KC, Chen PJ. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol Int. 2020 Dec;14(6):997-1008
  45. Indolfi G, Fischler B, Gonzalez-Peralta RP, Ciocca M, Porta G, Neelam M, El-Guindi M, Kelly D, Ni YH, Sibal A, Leung DH, Chang MH; Hepatitis Expert Team ofthe Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN). Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federationof International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN). J Pediatr Gastroenterol Nutr 2020; 70(5):711-717.
  46. Jan CF, Liu TH, Ho CH, Chien YC, Chang CJ, Guo FR, Huang KC. Doses of hepatitis B revaccination needed for the seronegative youths to be seropositive to antibody against hepatitis B surface antigen. Fam Pract. 2020 Feb 19; 37(1):30-5. (SCI)
  47. Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities Through Immunomodulation. Vaccines. 2020. May;8:247.
  48. Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics. 2020.May;10(5):338.
  49. Lai YH, Chung YA, Wu YC, Fang CT, Chen PJ. Disease burden from foodborne illnesses in Taiwan, 2012-2015. J Formos Med Assoc. 2020 Sep;119(9):1372-1381
  50. Lee BC, Hsieh ST, Chang YL, Tseng FY, Lin YJ, Chen YL, Wang SH, Chang YF, Ho YL, Ni YH, Chang SC. A Web-Based Virtual Microscopy Platform for Improving Academic Performance in Histology and Pathology Laboratory Courses: A Pilot Study. Anat Sci Educ. 2020 Nov;13(6):743-758
  51. Lee SY, Chao CT, Huang JW, Huang KC. Vascular Calcification as an Underrecognized Risk Factor for Frailty in 1783 Community-Dwelling Elderly Individuals. J Am Heart Assoc. 2020 Sep 15;9(18):e017308. (SCI)
  52. Li CM, Chao CT, Chen SI, Han DS, Huang KC. Elevated red cell distribution width is independently associated with a higher frailty risk among 2,932 community-dwelling older adults. Front Med (Lausanne). 2020 Aug 25;7:470. (SCI)
  53. Lim D, Ho CM. Appendicitis-mimicking presentation in fishbone induced microperforation of the distal duodenum: A case report. World Journal of Gastrointestinal Surgery 2020 Feb;12(2):77-84
  54. Lin CH, Ho CM, Wu CH, Liang PC, Hu RH, Lee PH, Ho MC. Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis. Surg Endosc. 2020 Dec;34(12):5566-5573
  55. Lin CL, Kao JH. Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence. Gastroenterol Clin North Am. 2020 Jun;49(2):201-214.
  56. Lin CL, Tseng KC, Chen KY, Liao LY, Kao JH. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. J Formos Med Assoc. 2020 Oct;119(10):1483-1489
  57. Lin GY, Wu YL, Wang CS, Ko CY, Chen CH, Chen PJ, Peng PH, Hsu CW. Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan. Virol J. 2020 Jun 16;17(1):76.
  58. Lin YC, Wu CC, Ni YH. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Front Pediatr. 2020 Dec 9;8:603654
  59. Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals. J Hepatol 2020;72:839-846.
  60. Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan. Liver Int 2020;40:758-768.
  61. Liu CH, Peng CY, Fang YJ, Kao WY, Yang SS, Lin CK, Lai HC, Su WP, Fang SU, Chang CC, Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. Sci Rep. 2020 Jun 8;10(1):9180.
  62. Liu CH, Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. J Formos Med Assoc. 2020 Dec;119(12):1871-1875
  63. Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020 Jan 25. doi: 10.1111/jvh.13265.
  64. Liu CJ, Chen PJ. Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. Viruses. 2020 Jul 28;12(8):815
  65. Liu CJ, Tseng KC, Lo CC, Tseng IH, Cheng PN. Limited drug-drug interaction of Elbasvir/Grazoprevir for chronic hepatitis C. J Formos Med Assoc 2020;119:933-940.
  66. Lu CY, Chen CL, Ho CM, Hsiao CY, Wu YM, Ho MC, Lee PH, Hu RH. Dynamic prognostication in transplant candidates with acute-on-chronic liver failure. J Pers Med. 2020 Nov 15;10(4):230
  67. Lu FT, Ni YH. Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatr Gastroenterol Hepatol Nutr. 2020 Jul;23(4):311-318
  68. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020 Feb 26;33(2):e00046-19.
  69. Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jun MJ, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; Real-World Evidence from the Asia Liver Consortium Investigators. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clin Infect Dis. 2020 Dec 31;71(11):2840-2848
  70. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228.
  71. Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DRC, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye V, Voutila J, Dorman S, Andrikakou P, Lloyd P, Felstead S, Vasara J, Habib R, Wood C, Saetrom P, Huber HE, Blakey DC, Rossi JJ, Habib N. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients With Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946
  72. Shen YC, Hsu CL, Jeng YM, Ho MC, Ho CM, Yeh CP, Yeh CY, Hsu MC, Hu RH, Cheng A. Reliability of a single-region tumor sample for evaluating the immune tumor microenvironment of hepatocellular carcinoma tumors. J Hepatol. 2020 Mar;72(3):489-497.
  73. Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses. 2020 Jul 10;12(7):741
  74. Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020 Oct;119(10):1476-1482
  75. Su TH, Kao JH. The clinical manifestations and management of COVID-19-related liver injury. J Formos Med Assoc. 2020 Jun;119(6):1016-1018.
  76. Su TH, Peng CY, Tseng TC, Yang HC, Liu CJ, Liu CH, Chen PJ, Chen DS, Kao JH. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. J Infect Dis. 2020 Feb 3;221(4):589-597.
  77. Su TH, Tseng TC, Liu CJ, Chou SW, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Kao JH. Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. Int J Cancer. 2020 Aug 1;147(3):901-908.
  78. Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Ke CK, Yu ML. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). Open Forum Infect Dis. 2020 Aug 31;7(10):ofaa397.
  79. Tseng HH, Tseng LW, Yang HC. Benzarone-induced liver injury: First case report in Asia. J Formos Med Assoc. 2020 Sep;119(9):1445-1447
  80. Tseng TC, Liu CJ, Chang CT, Su TH, Yang WT, Tsai CH, Chen CL, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. Cirrhosis Increases the Risk of Liver-related Mortality in Hepatitis B Patients Superinfected with Hepatitis E Virus. J Hepatol 2020 Mar 12. pii: S0168-8278(20)30029-5.
  81. Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, Yang HC, Yang WT, Lin CH, Yu ML, Lai HC, Tanaka Y, Nguyen MH, Liu CH, Chen PJ, Chen DS, Kao JH. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. Liver Cancer. 2020 Apr;9(2):207-220.
  82. Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. J Formos Med Assoc. 2020 Jan;119(1 Pt 2):335-344.
  83. Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020 Jan;51(2):216-230.
  84. Wang CC, Tzeng IS, Su WC, Li CH, Lin HH, Yang CC, Kao JH. The association of vitamin D with hepatitis B virus replication: Bystander rather than offender. J Formos Med Assoc. 2020 Nov;119(11):1634-1641
  85. Wang CY, Shih SR, Huang KC. Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer. J Diabetes Investig. 2020 Mar; 11(2):490-8. (SCI)
  86. Wang JT, Lin YY, Chang SY, Yeh SH, Hu BH, Chen PJ, Chang SC. The role of phylogenetic analysis in clarifying the infection source of a COVID-19 patient. J Infect. 2020 Jul;81(1):147-178
  87. Wen WH, Chen HL, Shih TT, Wu JF, Ni YH, Lee CN, Zhao LL, Lai MW, Mu SC, Tung YC, Hsu HY, Chang MH; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study)(‡). Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate. J Hepatol. 2020 Jun;72(6):1082-1087.
  88. Wu GH, Pwu RF, Chen SC, Chen DS. Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver Int. 2020 Jun;40(6):1506-1507.
  89. Wu JF, Chang KC, Ni YH, Hsu HY, Chang MH. Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion. J Infect Dis. 2020 Aug 29:jiaa545
  90. Wu JF, Ho MC, Ni YH, Hsu HY, Lee PH, Chang MH. Dysregulation of liver developmental microRNA contribute to hepatic carcinogenesis. J Formos Med Assoc 2020;119(6):1041-1051.
  91. Wu JW, Tseng TC, Liu CJ, Su TH, Liu CH, Chen PJ, Chen DS, Kao JH. Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. ADVANCES IN DIGESTIVE MEDICINE, Early Access: JUL 2020
  92. Yang HC, Kao JH. Towards elimination of viral hepatitis in Taiwan by 2025: In memory of Professor Ding-Shinn Chen (1943-2020). J Formos Med Assoc. 2020 Aug;119(8):1247-1248
  93. Yang HI, Kao JH, Liu CJ, Hu TH, Lu SN, Chen CH, Chen PJ, Lee CM, Liaw YF, Peng CY, Wu JC, Chuang WL, Ni YH, Huang HY, Chien RN. Taiwan consensus statementon the management of chronic hepatitis B. J Formos Med Assoc 2020; (in press)
  94. Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020 Jan 14;221(3):389-399.
  95. Yang PC, Huang KW, Pua U, Kim MD, Li SP, Li XY, Liang PC. Prognostic Factor Analysis of Irreversible Electroporation for Locally Advanced Pancreatic Cancer - a multi- institutional clinical study in Asia. European Journal of Surgical Oncology. 2020 May 46(5):811-817.
  96. Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids 2020 Mar 19;20:480-490. doi: 10.1016/j.omtn.2020.03.005.
  97. Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol. 2020 Oct;26(4):554-561. 
  98. Yeo YH, Tseng TC, Hosaka T, Cunningham C, Fung JYY, Ho HJ, Kwak MS, Trinh HN, Ungtrakul T,Yu ML, Kobayashi M, Le AK, Henry LD, Li JY, Zhang J, Sriprayoon T, Jeong D, Tanwandee T, Gane E, Cheung RC, Wu CY, Lok AS, Lee HS, Suzuki F, Yuen MF, Kao JH, Yang HI, Nguyen MH. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. Clin Transl Gastroenterol. 2020 Sep;11(9):e00196
  99. Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Lin HC, Kao JH, Chuang WL. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020 Jun;119(6):1019-1040.
  100. Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Lin HC, Kao JH, Chuang WL. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020 Jul;119(7):1135-1157.
  101. Zhang TY, Guo XR, Wu YT, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J, Yuan Q, Xia NS. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020 Feb;69(2):343-354.
     

新聞亮點

新聞報紙